This company has been marked as potentially delisted and may not be actively trading. Pharmacyclics (PCYC) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Summit Therapeutics: Not Pharmacyclics, Not YetApril 12, 2025 | seekingalpha.comWhich 10 prescription drug prices are dropping in 2026 after negotiations? What we knowAugust 19, 2024 | usatoday.com10 prescription drug prices are dropping in 2026: Here are the ones renegotiatedAugust 19, 2024 | usatoday.comDrugs to treat diabetes, heart disease and blood cancers among those affected by price negotiationsThe Biden administration says Medicare recipients will save about $1.5 billion dollars on medications to for diabetes, heart disease, types of arthritis and other ailments under new prices negotiated with drug companies that will take effect in 2026August 15, 2024 | marketbeat.comSummit Therapeutics sees stock soar 272% after lung cancer clinical trialMay 31, 2024 | bizjournals.comPCYC Historical DataSeptember 23, 2023 | investing.comPharmacyclics (PCYC) Stock Spikes Today Following $21 Billion AbbVie Merger DealMarch 24, 2023 | thestreet.comPharmacyclics Reaches New 52-Week High (PCYC)February 24, 2023 | thestreet.comPharmacyclics' Imbruvica Extends Survival in Elderly Leukemia PatientsJanuary 29, 2023 | thestreet.comASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)January 13, 2023 | thestreet.comStocks in Motion: PharmacyclicsJanuary 2, 2023 | thestreet.comPulnovo Medical Announces Dr. Krishna Sudhir Joins Scientific Advisory Board - StreetInsider.comJune 16, 2022 | streetinsider.comPulnovo Medical Announces Dr. Krishna Sudhir Joins Scientific Advisory Board - PR NewswireJune 15, 2022 | prnewswire.comNew IMBRUVICA® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia - StreetInsider.comJune 12, 2022 | streetinsider.comCritical Limb Ischemia Market to Progress at a CAGR of 10.6% by 2030 | DelveInsight - PR NewswireJune 7, 2022 | prnewswire.comArtiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer - Business WireJune 6, 2022 | businesswire.comGlobal Graft Versus Host Disease (GvHD) Treatment Market Report 2022: Corticosteroids Accounted for More - BenzingaJune 6, 2022 | benzinga.comCelularity Appoints Industry Leader Diane Parks to its Board of Directors - StreetInsider.comJune 3, 2022 | streetinsider.comRising Star: Covington & Burling's Brianne Bharkhda - Law360June 1, 2022 | law360.comReal Story: Cancer Drug ManiaApril 8, 2022 | thestreet.com Get Pharmacyclics News Delivered to You Automatically Sign up to receive the latest news and ratings for PCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address PCYC Media Mentions By Week PCYC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCYC News Sentiment▼0.001.08▲Average News Sentiment PCYC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCYC Articles This Week▼10▲PCYC Articles Average Week Get Pharmacyclics News Delivered to You Automatically Sign up to receive the latest news and ratings for PCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMGN News Today GILD News Today VRTX News Today REGN News Today ALNY News Today BIIB News Today UTHR News Today INCY News Today BMRN News Today EXEL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCYC) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmacyclics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharmacyclics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PCYC Stock Free PCYC Stock Alerts